CSDE1 (C-term), 588-615 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-CSDE1 (C-term), 588-615 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityCSDE1 (C-term), 588-615
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatpeptide affinity purified
Size0.08 mL, 0.4 mL
Concentrationvial concentration: 0.5
ApplicationsWestern Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionThis CSDE1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 588-615 amino acids from the C-terminal region of human CSDE1. CSDE1 is a RNA-binding protein. Required for internal initiation of translation of human rhinovirus RNA. May be involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain.
Immunogenn/a
Other Names[Cold shock domain-containing protein E1; N-ras upstream gene protein; Protein UNR; CSDE1; D1S155E; KIAA0885; NRU; UNR]
Gene, Accession #[CSDE1], Gene ID: 7812, NCBI: NP_001007554.1, UniProt: O75534
Catalog #MBS9203413
Price$165, $370
Order / More InfoCSDE1 (C-term), 588-615 Antibody from MYBIOSOURCE INC.
Product Specific ReferencesBailey, S.D., et al. Diabetes Care (2010) In press : Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) : Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009) Anderson, E.C., et al. J. Gen. Virol. 88 (PT 11), 3043-3052 (2007) : Wu, C., et al. Proteomics 7(11):1775-1785(2007)
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.